---
title: "Endurance RP Sets Sights on China Approval and Longevity Tech Growth After 2025 Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280648441.md"
description: "Endurance RP (HK:0575) reported its 2025 results, focusing on its strategy to generate royalties through out-licensing its drug portfolio. The company aims for approval of Senstend in China by June 2026, in partnership with Wanbang Biopharmaceutical. Endurance RP is also advancing its AI-driven longevity technologies, positioning Deep Longevity as a key future driver. The latest analyst rating for the stock is a Hold with a price target of HK$0.93. The company has a market cap of HK$245.1M and a year-to-date price performance of -21.50%."
datetime: "2026-03-26T14:16:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280648441.md)
  - [en](https://longbridge.com/en/news/280648441.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280648441.md)
---

# Endurance RP Sets Sights on China Approval and Longevity Tech Growth After 2025 Results

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Endurance RP ( (HK:0575) ) has provided an update.

Endurance RP reported its audited final results for 2025, highlighting continued progress as a commercial-stage biopharmaceutical company and its strategy to generate royalties and milestone payments by out-licensing its drug portfolio. The company emphasized disciplined capital management and ongoing investment in innovation to support long-term shareholder value.

Operationally, management underscored the importance of China and the wider Greater China region, where it is working with partner Wanbang Biopharmaceutical and regulators to secure approval for Senstend by June 2026 after a delay from the original late-2025 expectation. The company also reiterated its ambition to lead in the longevity space through its AI-driven ageing clocks, positioning Deep Longevity as a core driver of future health and wellness offerings.

The most recent analyst rating on (HK:0575) stock is a Hold with a HK$0.93 price target. To see the full list of analyst forecasts on Endurance RP stock, see the HK:0575 Stock Forecast page.

**More about Endurance RP**

Endurance RP, formerly known as Regent Pacific, is a Hong Kong-based biopharmaceutical and investment company focused on building a royalty-focused pharma business and advancing longevity technologies. Its primary assets include Fortacin, marketed as Senstend in China for premature ejaculation, and Deep Longevity, an AI-powered digital health unit offering ageing clocks and preventative health solutions via a B2B2C SaaS platform, with strategic focus on Greater China, the U.S., the U.K., and Europe.

**YTD Price Performance:** -21.50%

**Average Trading Volume:** 69,952

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$245.1M

### Related Stocks

- [00575.HK](https://longbridge.com/en/quote/00575.HK.md)

## Related News & Research

- [16:00 ETNIIMBL Announces 8 New Technology and Workforce Projects](https://longbridge.com/en/news/286959206.md)
- [08:02 ETTHE ACADEMY OF GEROSCIENCE WELCOMES SIXTEEN LEADING SCIENTISTS AS NEW MEMBERS](https://longbridge.com/en/news/286767633.md)
- [09:13 ETThe new Neurology-First Platform to Accelerate Clinical Trial Recruitment, Real-World Evidence, and Therapy Adoption](https://longbridge.com/en/news/286919710.md)
- [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md)
- [SignalEDI Launches AI‑Driven EDI Automation Platform to Modernize Supply Chain and Healthcare Data Exchange](https://longbridge.com/en/news/286689892.md)